Cancer and Crisis Talks with Jemma Arakelyan #2 – Dr. Layth Mula-Hussain
We are thrilled to unveil the next captivating episode of our enlightening series, “Cancer and Crisis Talks,” hosted by the remarkable Dr. Jemma Arakelyan. In our ongoing mission to shed light on the unique challenges faced by cancer care providers and patients during times of crisis, we are honored to present our distinguished guest for this episode: Dr. Layth Mula-Hussain.
About Dr. Layth Mula-Hussain:
Dr. Mula-Hussain was born, raised and gained his medical degree from the University of Mosul, all in Ninevah – Iraq. He travelled to Jordan to do a residency in radiation oncology at the King Hussein Cancer Center in Jordan, then to Germany to do MSc in advanced oncology at Ulm University and then did four years of clinical fellowships in Canada. Besides many professional memberships, he is a lifetime ESTRO Fellow & IAHPC member, ESCO Graduate, Certified Clinical Investigator, Fellow of the Royal College of Physicians of Edinburgh and ESO Ambassador by the European School of Oncology.
During his 20+ years in oncology, Dr. Mula-Hussain served as a consultant physician in radiation oncology at the King Hussein Cancer Center in Jordan, Zhianawa Cancer Center in Iraq, and Sultan Qaboos Comprehensive Cancer Centre in Oman. Currently, he is an attending physician at the Cape Breton Cancer Centre and an assistant professor at Dalhousie University in Nova Scotia – Canada, besides being visiting professor at Ninevah University in Iraq.
Dr. Mula-Hussain was the founding director of Iraq’s first radiation oncology board program (2013 – 2017). He acted as an Expert within imPACT IAEA teams for Pakistan (2013) & Syria (2022) and a member of the ASCO International Affairs Steering Committee (2016 – 2019). He authored / co-authored 80+ manuscripts/ books/ books’ chapters, did 100+ scientific presentations, and his efforts were cited over 800+ times with an H-index of 15.
About Dr. Jemma Arakelyan:
The host, Dr. Jemma Arakelyan, is a medical oncologist and a Ph.D. candidate at the City University of Hong Kong. Having graduated from both Yerevan State Medical University and Harvard Medical School, she is currently immersed in pursuing a Ph.D. in the dynamic field of anticancer drug discovery at the Drug Discovery Lab, City University of Hong Kong. Here, her research pursuits are pioneering innovative strategies to combat cancer and unearth novel therapeutic avenues for patients. Beyond academia, Dr. Arakelyan is deeply involved as an ESCO Fellow and an influential adviser at the Immune Oncology Research Institute. Since June 2023, she has been appointed the CEO of the Institute of Cancer and Crisis, overseeing initiatives to tackle cancer in the face of challenging circumstances.